In Q1 2026, Hemab Therapeutics completed a major corporate reorganization and raised approximately $346.7 million in an upsized IPO, substantially bolstering its liquidity and operational runway. The biotechnology company remains focused on advancing its lead bispecific antibody candidate, sutacimig (HMB-001), alongside HMB-002 in early-phase clinical trials targeting rare coagulation disorders such as Glanzmann thrombasthenia and Von Willebrand disease. While the company has no products on the market yet and continues to incur significant losses due to R&D expenses, these recent financial and structural developments position Hemab to pursue key clinical milestones. Risks persist around dependences on external collaborators, regulatory hurdles, and competitive pressures within the specialized coagulation therapeutics sector.